Every S-1 that Cbdmd Inc (YCBD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow YCBD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full YCBD filings page.
cbdMD, Inc. has filed a resale registration covering up to 2,000,000 shares of common stock issuable upon conversion of its Series C Convertible Preferred Stock and related stock dividends. These shares may be sold from time to time by the selling shareholders, and the company will not receive any proceeds from such resales.
The Series C Preferred Stock was sold in a December 2025 private placement, raising $2.25 million, and now has a fixed conversion price of $1.13 per share with a 10% annual dividend payable in stock or cash, subject to conditions and anti-dilution protections. Common shares outstanding were 10,495,561 as of February 19, 2026, and would be 12,495,561 assuming full Series C conversion.
The filing highlights significant risks: potential NYSE American delisting if listing standards are not maintained, substantial potential dilution from preferred stock, options, warrants and earnout shares, and new federal legislation that could cap THC content in hemp-derived consumables at 0.4mg per container, which the company states would likely have a material adverse impact on its business if implemented as written. cbdMD also notes its January 2026 acquisition of the Bluebird Botanicals brand, expected to contribute about $600,000 in quarterly revenue after integration.
cbdMD, Inc. has filed a Form S-1 to register the resale of up to 2,000,000 shares of common stock by existing investors. These shares are issuable upon conversion of the company’s Series C Convertible Preferred Stock and related initial dividend payments that were sold in a prior private placement.
The company already received $2,250,000 in gross proceeds from issuing 1,000,000 Series C preferred shares at a $2.25 conversion price per common share, subject to anti-dilution adjustments and a $0.65 floor. cbdMD will not receive proceeds from any resale under this prospectus. Common shares outstanding were 10,495,561 as of January 20–21, 2026, and resale methods may include ordinary broker transactions, market sales, and privately negotiated deals.
cbdMD, Inc. is registering up to 3,234,000 shares of common stock for potential resale by C/M Capital Master Fund, LP in connection with a committed equity financing facility. The shares include up to 3,154,000 purchase shares the company may sell to C/M Capital under a purchase agreement, plus up to 80,000 commitment shares issued as consideration for that agreement.
cbdMD may sell up to $20 million of stock to C/M Capital over 36 months, but will not receive any proceeds from the Selling Shareholder’s resale of these registered shares. Common stock outstanding was 10,068,203 shares as of December 30, 2025, and would rise to 13,302,203 shares if all registered shares are issued. NYSE American rules cap new issuances at 19.99% of pre-agreement shares unless pricing or shareholder approval conditions are met, and C/M Capital is subject to a 4.99% beneficial ownership limit, adjustable to 9.99% with notice.
The filing highlights risks around dilution, stock price pressure from discounted share sales, reliance on the equity line to meet capital needs, prior going concern doubts, and potential volatility in cbdMD’s NYSE American-listed stock.
cbdMD, Inc. has filed a resale registration covering up to 1,700,000 shares of common stock issuable upon conversion of its Series B Convertible Preferred Stock. These shares may be sold from time to time by the selling shareholders, and cbdMD will not receive any proceeds from their resale, having previously raised $1.7 million in gross proceeds when it sold 1,700,000 Series B preferred shares in a private placement. The Series B Preferred Stock converts at $1.00 per share, subject to anti-dilution with a $0.50 floor, and carries a 10% annual dividend payable in stock or cash if certain conditions are met. As of December 19, 2025, cbdMD had 8,959,410 common shares outstanding, or 10,659,410 shares assuming full Series B conversion at $1.00 per share. The company’s stock trades on the NYSE American under the symbol YCBD, with a last reported price of $1.93 on December 18, 2025.
cbdMD, Inc. filed an S-1 registering the potential resale of up to 1,700,000 shares of common stock by selling shareholders. The registered shares are issuable upon conversion of Series B Convertible Preferred Stock sold on September 29, 2025 pursuant to Purchase Agreements. cbdMD will not receive proceeds from any resale of these shares.
The Series B Preferred is convertible at $1.00 per share, subject to anti‑dilution adjustments and a floor conversion price of $0.50 per share, and accrues dividends at 10% per annum, payable in cash or stock subject to equity conditions. A 4.99% beneficial ownership limitation applies to conversions. An exchange cap limits issuances without prior shareholder approval to 19.99% of pre‑transaction outstanding shares, identified as 1,782,518 shares.
Shares outstanding were 8,919,410 as of November 6, 2025. The company states 10,619,410 shares outstanding assuming full conversion at a $1.00 conversion price. cbdMD previously received $1,700,000 gross proceeds from the private placement of the Series B Preferred for working capital and general corporate purposes.